A secondary mutation in BRAF confers resistance to RAF inhibition in a BRAF V600E-mutant brain tumor

BRAF V600E hyperactivates ERK and signals as a RAF inhibitor-sensitive monomer. While RAF inhibitors can produce impressive clinical responses in patients with mutant BRAF tumors, the mechanisms of resistance to these drugs are incompletely characterized. Here, we report a complete response followed...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancer Discov
Autores principales: Wang, Jiawan, Yao, Zhan, Jonsson, Philip, Allen, Amy N., Qin, Alice Can Ran, Uddin, Sharmeen, Dunkel, Ira J., Petriccione, Mary, Manova, Katia, Haque, Sofia, Rosenblum, Marc K., Pisapia, David J., Rosen, Neal, Taylor, Barry S., Pratilas, Christine A.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2018
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6125191/
https://ncbi.nlm.nih.gov/pubmed/29880583
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-17-1263
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares